



Regenerex Pharma, Inc.

Statistics:

OTCBB Symbol: RGPX

Web: regenerexpharmainc.com

52-week price range: \$XX- \$XX

Recent price (9-28):\$XX

Fiscal year ends: March 31

Market cap: \$XX million approx.

Average daily volume: XX approx.

Common shares: 277,437,660 (6-30)

About Us:

Regenerex Pharma, Inc. provides the most technologically advanced and clinically proven products on the market today that heal chronic wounds quicker, conveniently and cost effectively. The Company provides the wound care industry with a complete suite of products and protocols to treat all wounds which include chronic wounds, diabetic ulcers, pressure ulcers, burns and surgical wounds. Our unique products strategically position the Company to enter and capture a high proportion of market share in the U.S. and globally.

The Science of Our Products:

Our mission at Regenerex Pharma, Inc. is to heal wounds effectively with our proprietary innovative formulas in the shortest period of time to minimize the chances of future complications. Our products have shown to be very effective in healing chronic wounds in multiple clinical evaluations with 95% of wounds demonstrating 100% closure within 90 days. All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close.

Currently, there are no products available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases. Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids, but these dressings do not impact the cellular environment with simple gauze and gauze-like dressings to cover and protect the wound.

1 XCELLDERMA OTC- Liquid Bandage Skin Protectant



Xcellerma™ products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx™ the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).

2 ACCELEREX Sterile Wound Cream



The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA & CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx™. Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company's broadly-enabling technology was discovered from oak bark extract and referred to as QBx™.

3 ACCELEREX IMPREGNATED STERILE WOUND DRESSING



For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination device that blends the benefits of a wound dressing with two drug components. Provides 3 modes of action to help treat acute and chronic wounds:

Protective dressing, moisturizing ointment and 2 drug components: rubidium chloride and potassium chloride.



Regenerex Pharma Advantages

We manufacture and market the most efficacious, clinically proven advanced chronic wound care product line in the world. Wounds that don't heal detract from your quality of life and prevent you from doing things you enjoy. Regenerex's products provide advanced wound care that can stimulate healing effectively and in shorter period of time compared to traditional methods. Our QBx™ technology contributes to setting up a suitable environment to allow wounds to close. We are proud to serve the needs of our population to successfully heal chronic, non-healing wounds through our products that provide down regulation of proteases.

Officers and Directors

Mr. Gregory P. Pilant
CEO, Chairman of the Board, Director

Dr. Lee Ori
Chief R&D Officer, Director

Ms. Deborah Pilant
CFO, Secretary/Treasurer, Director

Mr. Troy Thuet
VP Manufacturing

Executive Leadership

Ms. Marsha McNair
VP Operations

Mr. R. Dan Winnett
Exec. VP, In-house Counsel

Mr. Damon Faulkner
VP Sales & Marketing

Mr. Chris Hendrix, M.D.
Clinical Director

Ms. Tasha D. Kennon, RN, BS
Clinical Training Director

Mr. Brad Cleaver
Channel Sales Director

Mr. John Nycz
Marketing Director

Corporate Information:

HEADQUARTERS OFFICE:
5348 Vegas Drive, Suite 177
Las Vegas, NV 89108
Corporate Ph: (877) 761-RGPX
Investors Ph: (305)-927-5191
info@regenerexpharmainc.com

AUDITORS:
Michael L. McKennon
DBB McKennon
Newport Beach, CA

TRANSFER AGENT:
Pacific Stock Transfer
Las Vegas, NV
Cusip #: 713468106

Executive Office:
619 Main St.
Carthage, TN 37030

Manufacturing Office:
1749 Florida Street
Memphis, TN 38109